Neurosterix raises USD 105 million in Series B funding
16 November 2026
Neurosterix develops treatments for neuropsychiatric disorders, such as schizophrenia, by fine-tuning brain signaling. | © Neurosterix
Geneva-based Neurosterix, a clinical-stage biotech spun out of Addex Therapeutics in 2024, has closed a USD 105 million Series B round led by RTW Investments to advance NTX-253 into a phase 2 trial in schizophrenia.
Neurosterix has closed a USD 105 million Series B round led by RTW Investments. New investors Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors and Dellora Investments joined the round, alongside existing investors Perceptive Advisors and Acorn Bioventures.
The funding will mainly advance NTX-253 into a phase 2 trial in schizophrenia and support the company’s broader portfolio of selective allosteric modulators for neuropsychiatric disorders. Neurosterix was spun out of Addex Therapeutics in 2024 and launched with USD 63 million.
A pipeline built on allosteric modulation
NTX-253, the lead program, is a brain-penetrant, selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target in schizophrenia. It has completed phase 1 single and multiple ascending dose studies, and pharmacokinetic data support once-daily oral dosing.
NTX-819 is a potentially first-in-class negative allosteric modulator of the mGlu7 receptor, with preclinical results in models related to stress, mood and aggression. NTX-529 is a second M4 positive allosteric modulator, aimed at psychosis- and mood-related disorders. Behind the pipeline, Neurosterix holds a proprietary library of more than 80,000 compounds, more than 200 functional CNS assays and more than 100 patent filings.